Edition:
United Kingdom

Calyxt Inc (CLXT.OQ)

CLXT.OQ on NASDAQ Stock Exchange Global Market

9.88USD
14 Dec 2018
Change (% chg)

$0.43 (+4.55%)
Prev Close
$9.45
Open
$9.32
Day's High
$9.95
Day's Low
$9.32
Volume
56,497
Avg. Vol
20,269
52-wk High
$26.66
52-wk Low
$9.14

Summary

Name Age Since Current Position

Andre Choulika

53 2010 Chairman of the Board

James Blome

2018 Chief Executive Officer

Eric Dutang

45 2018 Interim Chief Financial Officer

Joseph Saluri

50 2017 General Counsel, Executive Vice President – Corporate Development

Daniel Voytas

55 2010 Chief Scientific Officer

Glenn Bowers

65 2015 Vice President - Breeding

Michel Arbadji

53 2015 Director of Business Development

Manoj Sahoo

42 2017 Chief Commercial Officer

Laurent Arthaud

55 2017 Director

Jonathan Fassberg

2018 Director

Alain Godard

72 2017 Director

Yves Ribeill

58 2018 Director

Philippe Dumont

66 2017 Independent Director

Anna Kozicz-Stankiewicz

43 2017 Independent Director

Christopher Neugent

57 2018 Independent Director

Biographies

Name Description

Andre Choulika

Dr. Andre Choulika, Ph.D., is Chairman of the Board of the company since August 2010Dr. Choulika is one of the founders of Cellectis, and has served as Chief Executive Officer of Cellectis since the company’s inception in 1999. He has served as the Chairman of the Board of Directors of Cellectis since 2011. Since December 2014, Dr. Choulika has served as Chief Executive Officer of Cellectis, Inc. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from HEC (Challenge +). Based on Dr. Choulika’s deep knowledge of our company and scientific experience, we believe Dr. Choulika has the appropriate set of skills to serve as a member of our Board of Directors.

James Blome

Mr. James A. Blome is Chief Executive Officer of the Company. Jim Blome grew up on a family corn and soybean farm in Hubbard, Iowa and a graduate of Iowa State University. Prior to joining Calyxt, Jim was the President and CEO for Bayer CropScience LP (North America). He held executive positions at Valent (Sumitomo Chemical) and Agriliance LLC before joining Bayer. Jim serves as the Chairman of CropLife America, Chairman of US Farming and Ranching Foundation, the Independent, Non-Executive Chairman of Concentric Ag Technologies, Inc. Jim is the 2013 recipient of the Henry A. Wallace Award from Iowa State University for outstanding leadership and service to agriculture. Kincannon & Reed, a leading executive search firm focused on the food, agribusiness, and biosciences sectors, assisted Calyxt

Eric Dutang

Mr. Eric Dutang is Interim Chief Financial Officer of the company. He currently serves as Chief Financial Officer of Cellectis S.A. (“Cellectis”) which owns 70.4% of the Company’s shares of common stock. Prior to joining Cellectis in May 2015, Mr. Dutang began his career as financial auditor with KPMG in Paris and in New York. He then became a member of the transactions and advisory teams in Paris for seven years where he carried out acquisitions/disposals for both publicly-traded companies and private equity funds. After serving at KPMG, he worked on international business developments for French publicly-traded groups, including Air Liquide and Thales. Mr. Dutang holds a Master of Finance and Executive MBA from HEC Paris (France)/Babson Massachusetts (USA).

Joseph Saluri

Mr. Joseph B. Saluri, J.D., is General Counsel, Executive Vice President – Corporate Development of the company since May 2017. He holds a Juris Doctorate from Drake Law School and a B.S.B.A. in investment finance from Drake University. Mr. Saluri has over 20 years of legal and business experience in in the global seeds and biotechnology industry, having served as Chief Legal Officer and Vice President of Business Development for Stine Seed Company, the largest supplier of soybean genetics in the U.S. market, together with its affiliates and related entities. Mr. Saluri was responsible for managing all legal matters related to the Stine Companies. He has a broad depth of experience in litigation, licensing, intellectual property, acquisitions, corporate and regulatory matters. In addition, Mr. Saluri also executed successful business development strategies at Stine that included the acquisitions of seed trait technologies, seed genetics and other ag-biotech technologies. He was involved in the execution and project management of major collaboration projects with various multinational agri-business corporations. Mr. Saluri has served on the public Board of Directors of Newlink Genetics Corporation since 2010, serving on the Compensation and Nominating and Governance Committees and on the Board of Directors of KemPharm, Inc. since 2014, where he chairs the Nominating and Governance Committee and serves on the Audit Committee. Previous to his employment at Stine, Mr. Saluri was an attorney and solicitor at law with Nicholas Critelli & Associates, PC, in Des Moines and London.

Daniel Voytas

Prof. Daniel F. Voytas, Ph.D., is Chief Science Officer of the company since May 2010. Dr. Voytas graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is one of our co-founders and one of the inventors of the TALEN technology. He continues to optimize the use of TALEN for the targeted modification of plant genomes. In addition to his role at Calyxt, Dr. Voytas is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota (UMN), which he joined in 2008, and Director of the UMN’s Center for Genome Engineering. In 1992, Dr. Voytas joined the faculty at Iowa State University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dr. Voytas is an elected Fellow of the American Association for the Advancement of Science.

Glenn Bowers

Mr. Glenn Bowers, Ph.D., is Vice President of Breeding of the company since December 2015. He is responsible for breeding, field trialing and seed production for all crops. Dr. Bowers has M.S. and Ph.D. degrees in Plant Pathology with a focus on breeding and genetics of resistance. He spent 17 years managing a soybean breeding program with Texas A&M University, followed by a year doing the same at Purdue University. He then spent 16 years with Syngenta, first managing a soybean breeding program and then as global head of soybean breeding. He has extensive experience in Argentina and Brazil, in addition to North America. He is also a certified project manager (PMP). Dr. Bowers has extensive experience in delivering products, both global and stateside, through effective collaboration with marketing and supply chain. He is skilled in creating, developing, and managing diverse and globally dispersed teams. He has a deep knowledge of and experience in field trialing, disease phenotyping, and agronomy.

Michel Arbadji

Mr. Michel Arbadji is Director of Business Development of the company since July 2015. Mr. Arbadji manages the external supply chain operations. Mr. Arbadji received his degree in Agriculture Engineering and M.A. in Economics and Agriculture Machinery from the Institut National Agronomique Paris Grignon in Paris, France. Prior to joining us, he headed the European and Middle East Operation for Signature Control Systems, build and managed the distribution network, EU marketing and sales. During that period he managed as project manager the new business development of the golf Irrigation division in Europe at John Deere with over 440 accounts. Mr. Arbadji started his career at the Toro Company EMEA, where he held several positions in business development, sales and marketing. Over his 27 years career he successfully built several sat Cellectis he served as CEO for Sceil the stem cells project (2013 – 2015). He is skilled in negotiation, communication and in delivering complex tasks.

Manoj Sahoo

Mr. Manoj Sahoo is Chief Commercial Officer of the company since March 2017. He holds a MBA from the Tuck School of Business at Dartmouth College and a B.S. in Chemical Engineering from the National Institute of Technology in India. Mr. Sahoo has more than two decades of experience working in a variety of roles covering commercial, strategy, business development and mergers and acquisitions for global corporations in agriculture, food, energy and materials fields. Prior to joining us he was Assistant Vice President for Food Ingredients and Bio-industrial Enterprise at Cargill. At Cargill, he was responsible for revenues of over $1 billion, leading the commercial enterprise team to triple its earnings from bio-based products and managing relationships with large institutional customers. His prior roles at Cargill included Business Development Director for Starches and Sweeteners North America as well as serving as an investment team member with the Emerging Business Accelerator, a group structured along corporate venture capital groups, to invest in white space opportunities for Cargill; he also worked in the Corporate Strategy & Development Group. Mr. Sahoo has also served on the boards of both Calysta Inc. and Rivertop Renewables as a Cargill representative. He was responsible for leading Cargill’s equity investments in the industrial biotechnology space including co-investment in real assets with institutional financial investors to build a $600 million commercial-scale aquaculture nutrition plant. He also serves on Industry Advisory Board of Larta Institute which assists the USDA, NIH and NSF with the commercialization assistance program.

Laurent Arthaud

Mr. Laurent Arthaud is Director of the company since July 2017. He has served as a member of Cellectis’ board of directors since 2011. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies for Bpifrance Investissement (formerly CDC Enterprises, a subsidiary of Caisse des Dépôts) since 2012. He currently serves on the boards of directors of Kurma Life Sciences Partners, TxCell, Adocia and Sparinvision. From 2006 to 2016, he served on the board of directors of Emertee Gestion. From 2006 to 2012, Mr. Arthaud held the position of Deputy CEO at CDC Entreprises. Since 2009 Mr. Arthaud has also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program. From 1999 to 2004, he served as Vice President of Aventis Capital, an investment subsidiary of the pharmaceuticals group Aventis, and as President of Pharmavent Partners from 2004 to 2006. Mr. Arthaud is a graduate of the École Polytechnique and the École Nationale de Statistique et d’Administration Économique.

Jonathan Fassberg

Mr. Jonathan Fassberg is Director of the Company. He is founder of the Trout Group and currently Co-Chief Executive Officer of Solebury Trout. He is member of the Audit Committee.

Alain Godard

Mr. Alain Godard is Director of the company since July 2017. He is a member of Cellectis’ board of directors since 2007. He is a graduate of the Ecole Nationale Supérieure Agronomique de Toulouse and began his agronomy career in 1967 in Africa as a researcher at the Institut de Recherche pour les Huiles et Oléagineux. He joined in 1975 the French chemical group Rhône-Poulenc where he held various management positions in France and abroad before becoming CEO of the agrochemical subsidiary in 1991. In 1999 he was directly involved in the merger of Rhône-Poulenc and Hoechst to create Aventis and was appointed CEO of the Aventis CropScience subsidiary with a significant involvement in seeds and agricultural biotechnology. He left Aventis in 2002 to create a consulting company, SARL Godard & Co., specialized in agriculture and biotechnology, where he has served as Chief Executive Officer since 2009. Until 2016, Mr. Godard also served on the board of directors of Fermentalg S.A.

Yves Ribeill

Dr. Yves Joseph Ribeill, Ph.D., is Director of the Company. He founded SCYNEXIS, Inc (NASDAQ: SCYX) and served as President and CEO from 1999 to 2015. Dr. Ribeill has more than 35 years of experience in the healthcare industry, with an expertise in anti-infective diseases including bacterial, fungal, viral and parasiticidal and in microbiome-centric diseases. Prior to moving to the U.S. 21 years ago, Dr. Ribeill held several management positions during his international career with Rhône-Poulenc and Aventis in France and in the UK. Dr. Ribeill was a member of the Scientific Advisory Committee of the World Health Organization, the Medicines for Malaria Venture and is currently Vice Chairman of the Triangle Global Health Consortium in North Carolina.

Philippe Dumont

Mr. Philippe Dumont is Independent Director of the company since July 2017. Mr. Dumont retired in December 2012 from Bayer CropScience, where he was employed since May 2002. At Bayer he held the position of Head of Technology Management, Seeds, and was responsible for supervising globally the Regulatory Affairs and Regulatory Science functions, Stewardship, Public and Governmental Affairs and Communication impacting GMOs and seeds. Until 2006 Mr. Dumont also supervised the Legal and Intellectual Property functions in the seed business. Mr. Dumont also held the same responsibilities at Aventis Crop Science from December 1998 until April 2002. From 1987 to 1998, Mr. Dumont was General Counsel of Rhône-Poulenc Agrochimie. Prior to moving to France in 1987, Philippe held positions as an associate at Cravath Swaine & Moore (1975 – 1981), international legal counsel at Gulf Oil Corporation (1981-1983) and as solo practitioner in Washington D.C. from 1983 – 1986. Philippe is retired from the New York and District of Columbia Bars and is a graduate of the Georgetown University Law Center (JD 1975) and Columbia University (BA, magna cum laude 1972). Since June 2013 he has been serving as a director of Association Française des Biotechnologies Végétales, responsible for international relations, where he tries to promote public and governmental understanding of new breeding techniques and related regulatory issues. Based on his leadership and regulatory experience in the plant biotechnology industry, we believe Mr. Dumont has the appropriate set of skills to serve as a member of our Board of Directors.

Anna Kozicz-Stankiewicz

Ms. Anna Ewa Kozicz-Stankiewicz is Independent Director of the company since July 2017. Mrs. Kozicz received a BA in Math and Economics from Columbia College and her MBA from Columbia Business School. She started her career in 1996 at Credit Suisse First Boston in its Financial Institutions Group before moving to Goldman Sachs in 2000 where she held multiple positions, including Managing Director, and spent most of her time in the Principal Strategies Group with a focus on the global agricultural sector. She moved to Caxton Associates in 2009 to work as an equity Portfolio Manager before moving to BlackRock in 2012 where she worked as Head of US Strategy and Corporate Development as well as a private assets Portfolio Manager. During her time at BlackRock, she served as a director on the board of a New York-based federal credit union (PSFCU). She left BlackRock in 2017 to start a new investment platform, Anthelion Capital, focused on sustainability in agriculture, energy and transportation services.

Christopher Neugent

Mr. Christopher J. Neugent serves as Independent Director of the Company. Mr. Neugent, has served as the Executive Vice President of Strategy of Post Holdings, Inc. since July 2018. Prior thereto, he served as President and CEO, Post Consumer Brands, from November 2015 until July 2018. Previously, Mr. Neugent served as the President and Chief Executive Officer of MOM Brands Company since May 2015, when Post acquired MOM Brands Company. From 2001 until the acquisition, Mr. Neugent served in various roles at MOM Brands Company, most recently as Chairman and CEO. Mr. Neugent has served on the Board of Directors of Welch Foods Inc. since February 2016. He holds a Bachelor of Arts degree in economics from Princeton University and completed the Advanced Management Program at the Wharton School of Business. Mr. Neugent has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors.